Impact of induction intensity and transplantation on outcomes of patients with complex karyotype and TP53-mutated acute myeloid leukemia

Jamy, Omer; Diebold, Kendall; Davis, Kenneth B.; Bachiashvili, Kimo; Rangaraju, Sravanti; Vachhani, Pankit; Godby, Kelly N.; Salzman, Donna; Bhatia, Smita

doi:10.1038/s41409-023-01977-7

Search citation statements

Order By: Relevance

Paper Sections

Select...

Who Should Receive Post-hct Maintenance Therapy?1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite1

Independent0

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…AML and MDS harboring TP53 mutations have dismal outcomes, even after proceeding to allo-HCT [ 45 ]. Hence, there is a need for targeted agents for this high-risk population.…”

Section: Who Should Receive Post-hct Maintenance Therapy?mentioning

confidence: 99%

Post-Transplant Maintenance Therapy in Acute Myeloid Leukemia

Parks,

Aslam,

Kumar

et al. 2024

Cancers

Self Cite

View full text Add to dashboard Cite

Allogeneic hematopoietic cell transplantation (allo-HCT) is potentially curative for patients with acute myeloid leukemia (AML). However, the post-transplant relapse rate ranges from 40 to 70%, particularly with reduced intensity conditioning, and remains a major cause of treatment failure for these patients due to the limited efficacy of salvage therapy options. Strategies to mitigate this risk are urgently needed. In the past few years, the basic framework of post-transplant maintenance has been shaped by several clinical trials investigating targeted therapy, chemotherapy, and immunomodulatory therapies. Although the practice of post-transplant maintenance in AML has become more common, there remain challenges regarding the feasibility and efficacy of this strategy. Here, we review major developments in post-transplant maintenance in AML, along with ongoing and future planned studies in this area, outlining the limitations of available data and our future goals.

show abstract

“…AML and MDS harboring TP53 mutations have dismal outcomes, even after proceeding to allo-HCT [ 45 ]. Hence, there is a need for targeted agents for this high-risk population.…”

Section: Who Should Receive Post-hct Maintenance Therapy?mentioning

confidence: 99%